| Name | Title | Contact Details |
|---|
Heartland Dental Care is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
The Medical Affairs Company is a Kennesaw, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Wedgewood Pharmacy is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Swedesboro, NJ. To find more information about Wedgewood Pharmacy, please visit www.wedgewoodpharmacy.com
TBH is a leading provider of behavioral health services. We specialize in the treatment of children and adults with Autism Spectrum Disorders and developmental disabilities, using the principles of Applied Behavior Analysis (ABA). TBH is proud to employ a talented staff dedicated to its mission and values, constructing a team of experienced, caring and enthusiastic individuals to coordinate the best behavior program possible for children, adults and families. Further, TBH`s collaborative efforts mean that parents, schools, agencies, Supervisors and Skills Trainers all play important roles in behavior programs, forming a large team dedicated to the needs of each client. TBH employs many Board Certified Behavior Analysts, and each Behavioral Consultant, also known as a Supervisor, is carefully screened to meet the qualifications set forth by TBH as well as those of the Behavior Analyst Certification Board (BACB). Further, each Skills Trainer, also known as a Paraprofessional, is screened using the same criteria. Behavioral Consultants and Skills Trainers are selected for clients on a case-by-case basis with careful consideration given to education, level of experience, and personality compatibility with the family and child.
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.